Iterion Therapeutics
PrivateLast Round
Grant
Feb 16, 2022
Total Funding Raised
$41.91M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Iterion Therapeutics is a clinical-stage biopharmaceutical company that develops novel targeted cancer therapeutics, including its lead product tegavivint, a first-in-class small molecule inhibitor of TBL1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iterion Therapeutics Comparables
Compare Iterion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sapience Therapeutics | 85% | |
| Redx Pharma Plc | 82% | |
| StemSynergy Therapeutics, Inc. | 81% |
Iterion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 16, 2022 | ||||
| Series B | Feb 16, 2021 | ||||
| Series B | Dec 5, 2018 | ||||
| Grant | Feb 19, 2014 |
Iterion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GOOSE Capital | Series B |
| GPG Ventures | Series B |
| Viva BioInnovator | Series B |
| Venture Investors LLC | Series B |
| Lumira Ventures | Series B |
| Cancer Prevention and Research Institute of Texas | Grant |
| AngelMD | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 37% MoM, from 917 to 1.3K.
- Feb 16, 2022
Received $3M from the Cancer Prevention and Research Institute of Texas.
Recent news
Latest coverage and updates
- receives_financingAug 12, 2026
Iterion Therapeutics receives $26M in Product Development Awards from the Cancer Prevention and Research Institute of Texas to support its development efforts.
- hiresAug 12, 2026
On Aug 12th '26, Iterion Therapeutics appoints Bob Smith as an independent director as it expands tegavivint's oncology development program and pursues strategic partnering opportunities.
- hiresAug 12, 2026
Iterion Therapeutics appoints Manuel Aivado, MD, PhD as an Independent Board Member alongside Bob Smith in Texas on Aug 12th '26, strengthening its board as it advances tegavivint.
- hiresAug 12, 2026
Iterion Therapeutics appoints Bob Smith as an Independent Board Member in Texas on Aug 12th '26, alongside Manuel Aivado, MD, PhD, strengthening its leadership as it advances tegavivint and expands into additional Wnt-driven cancers.
Iterion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iterion Therapeutics's valuation, stock price, and market status.
Is Iterion Therapeutics a public or private company?
Iterion Therapeutics is a private company.
What is the current stock price of Iterion Therapeutics?
Iterion Therapeutics is a private company, so its shares have no public market price. Caplight tracks Iterion Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Iterion Therapeutics worth (valuation)?
Valuation information for Iterion Therapeutics is not publicly available.
Can I buy Iterion Therapeutics stock?
Iterion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Iterion Therapeutics's last funding round?
Iterion Therapeutics's most recent funding round was Grant on February 16, 2022.
Who are the main investors in Iterion Therapeutics?
Key investors in Iterion Therapeutics include Lumira Ventures.
Will Iterion Therapeutics IPO soon?
No public IPO plans have been announced for Iterion Therapeutics.
How can I track Iterion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Iterion Therapeutics's shares on secondary markets.